PRNewsWire
21 May 2026, 19:45 UTC · 17w ago
Verdict
Headline takes no side. We score ERAS −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Revolution Medicines has alleged that Erasca's ERAS-0015 infringes on a patent and involves trade secret misappropriation.
More negative than 99% of claims this week
Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Erasca and its officers.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
Erasca's stock price plummeted 48.3% to $9.90 on April 28, 2026, following the disclosure of the patent dispute.
So whatThis confirms a severe negative market reaction and establishes a new, lower valuation floor based on the perceived risk.
More negative than 71% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud investigation and a patent infringement lawsuit that caused a 48.3% drop in stock price.
More negative than 76% of ticker scores this week
The company is the subject of an investigation by the Pomerantz Law Firm on behalf of investors.
More negative than 76% of ticker scores this week
The company is the subject of an investigation by the Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
+25.4%
Price is moving against the score
$13.95 vs $11.12 close before publication (May 20) · not market-adjusted
ERAS chart →
